Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Recipient : Quantum Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Details : Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.
Brand Name : QGC001
Molecule Type : Small molecule
Upfront Cash : $12.1 million
December 15, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Quantum Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?